Clinical Trial

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk prostate cancer and standard therapies available to treat your disease have not been effective. Participation in this research will last about 3 years and 9 months.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-02-02; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2024-04-08
Trial Details
NCT Number NCT05726292
Lead Sponsor University of Chicago
Conditions Prostate Cancer, Prostate Adenocarcinoma
Enrollment 90 participants
Start Date 2025-01-06
Primary Completion 2027-10-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-04